A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 30, Issue 1, 2007, Pages 78-81

  Gaui, Maria De Fátima Dias ^a,c   Amorim, Gilberto ^a   Arcuri, Roberto Alfonso ^a   Pereira, Guilherme ^a   Moreira, Denise ^a   Djahjah, Célia ^a   Biasoli, Irene ^b   Spector, Nelson ^b  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c NONE   (Brazil)

Author keywords

Capecitabine; Locally advanced breast cancer; Neoadjuvant treatment; Radiosensitizing agents

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; LYMPH NODE; MICROSCOPY; MUCOSA INFLAMMATION; NAUSEA; PHASE 2 CLINICAL TRIAL; RADIATION DOSE; TUMOR VOLUME; VOMITING;

ADULT; AGED; ANTHRACYCLINES; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; LYMPH NODE EXCISION; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 33846837295     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000245475.41324.6d     Document Type: Article

References (14)

1. Schwartsmann G. Breast cancer in South America: challenges to improve early detection and medical management of a public health problem. J Clin Oncol. 2001;19:118-124.
2. Wood WC, Muss HB, Solin LJ, et al. In: de Vita VTJ, Hellman S, Rosenberg SA, eds. Cancer Principles & Practice of Oncology, ed. 7. Philadelphia: Lippincott Williams & Wilkins; 2005:1399-1487.
3. Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer. 1988;62:2507-2516.
4. Carlson RW, Anderson B, Chopra R, et al. Treatment of breast cancer in countries with limited resources. Breast J. 2003;9:67-74.
5. Huang E, Buzdar AU, Buhholz TA, et al. Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. Int J Radiat Oncol Biol Phys. 2002;53:1225-1233.
6. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274-1281.
7. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2812-2823.
8. Lebowitz PF, Eng-Wong J, Swain SM, et al. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res. 2004;10:6764-6769.
9. Woodward WA, Strom EA, Tucker SL, et al. Changes in the 2003 American Joint Committee on Cancer Staging for Breast Cancer dramatically affect stage-specific survival. J Clin Oncol. 2003;21:3244-3248.
10. National Cancer Institute: cancer therapy evaluation program: common toxicity criteria. Available at http://ctep.cancer.gov/reporting/CTC-3test. html. August, 1999. Accessed December, 2005.
11. Stearns V, Singh B, Tsangaris T, et al. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res. 2003;9:124-133.
12. Fischer B, Byrant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672-2685.
13. Bertheau P, Lerebours F, Mounier N, et al. Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer. Oncol Rep. 2005;14:513-520.
14. Gaui MF, Salgado R, Spector N, et al. Second-line neoadjuvant chemotherapy with cisplatin, 5-fluorouracil and radiotherapy for locally advanced breast cancer refractoy to anthracyclines: evaluation after a long-term follow up. Proc Am Soc Clin Oncol. 2004;23:27[Abstract 602].